BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tasly Pharmaceutical Group readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Tasly Pharmaceutical Group's drug
 s run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07265349-613@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:HucMSC intramyocardial therapy: Phase 1/2 readout est. (NCT07265349
 )
DESCRIPTION:HucMSC intramyocardial therapy\, phase 1/2\, Heart Failure.\nSt
 udy: A Phase I/II Clinical Trial of Intramyocardial Injection of HucMSCs f
 or the Treatment of Chronic Heart Failure\nEstimated primary completion: 3
 1 December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/hucm
 sc-intramyocardial-therapy#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07265349
URL:https://assetmemo.bio/drug/hucmsc-intramyocardial-therapy#upcoming-even
 ts
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06669169-639@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jia Shen Tablet: Phase 2 readout est. (NCT06669169)
DESCRIPTION:Jia Shen Tablet\, phase 2\, Heart Failure.\nStudy: Efficacy and
  Safety of Jia Shen Tablets in Chronic Heart Failure\nEstimated primary co
 mpletion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/jia-shen-tablet#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT06669169
URL:https://assetmemo.bio/drug/jia-shen-tablet#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06325566-10810@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:rexlemestrocel-L: Phase 3 readout est. (NCT06325566)
DESCRIPTION:rexlemestrocel-L\, phase 3\, Chronic Low Back Pain.\nStudy: Eff
 icacy and Safety of Rexlemestrocel-L Combined With HA* in Participants Wit
 h Moderate to Severe Chronic Low Back Pain\nEstimated primary completion: 
 July 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/rexlemestr
 ocel-l#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT06325566
URL:https://assetmemo.bio/drug/rexlemestrocel-l#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07687186-640@assetmemo.bio
DTSTAMP:20261121T010126Z
DTSTART;VALUE=DATE:20280622
DTEND;VALUE=DATE:20280623
SUMMARY:QiShenYiQi: Phase 3 readout est. (NCT07687186)
DESCRIPTION:QiShenYiQi\, phase 3\, Heart Failure.\nStudy: Qishen Yiqi Dripp
 ing Pills in Treatment of Chronic Heart FailUre\nEstimated primary complet
 ion: 22 June 2028. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/qi
 shenyiqi#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT07687186
URL:https://assetmemo.bio/drug/qishenyiqi#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
